Salute e Benessere

AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B…

Third asset to advance into clinical trials, validating broad potential of Launch-iT platformAll subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule Potential first-in-class treatment that could form part of functional cure for over 250 million patients suffering from chronic hepatitis B virus (HBV) infectionLeuven, Belgium, June 5, 2025–AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments...
Nasdaq GlobeNewswire
05/06/2025

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American…

Geneva, Switzerland, June 5, 2025-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that preclinical data from its gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) cough program will be presented at the 10 thAmerican Cough Conference (June 6-7) in Dulles, VA. A presentation given by Mikhail...
Nasdaq GlobeNewswire
05/06/2025

Global Anticancer Drugs Market Booms with 11.3% CAGR, Driven by Targeted Therapy…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-25M6948/Global_Anticancer_Drugs_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-25M6948/Global_Anticancer_Drugs_Market Major Factors Driving the Growth of Anticancer Drugs Market: The anticancer drugs market is experiencing robust growth fueled by rising cancer incidence, expanding treatment options, and technological advances. With increasing adoption of...
PR Newswire
05/06/2025

Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale…

Visitors were particularly impressed by Tsingke's automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company's ability to integrate reagents, instruments, and services into a unified platform drew significant attention from pharmaceutical and biotech partners. Visitors were particularly impressed by Tsingke's automation capabilities and flexible modular equipment designed to support…
PR Newswire
05/06/2025

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented…

Data from the ongoing Phase 1/2 clinical trial (NCT05914116) in patients with heavily pre-treated castration-resistant prostate cancer (CRPC) were presented during an oral session on BNT324/DB-1311, an B7H3-targeted ADC candidate. Data from the ongoing Phase 1/2 clinical trial (NCT05914116) in patients with heavily pre-treated castration-resistant prostate cancer (CRPC) were presented during an oral session on BNT324/DB-1311, an B7H3-targeted ADC candidate. The data indicated early clinical...
PR Newswire
05/06/2025

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary…

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.Alvotech has carried out a...
Nasdaq GlobeNewswire
05/06/2025

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in…

By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. "Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression", explained lead investigator Professor Jonathan Barratt. By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key…
PR Newswire
05/06/2025

Follicular Lymphoma Market Growth Accelerates at a CAGR of 6% During the…

First-line treatment for follicular lymphoma is well-established, with most patients experiencing durable responses to chemoimmunotherapy (CIT). For patients with localized disease, radiotherapy (RT) alone or in combination with immunochemotherapy is commonly used. RT alone may also be an option for localized relapses. First-line treatment for follicular lymphoma is well-established, with most patients experiencing durable responses to chemoimmunotherapy (CIT). For patients with localized...
PR Newswire
04/06/2025

Information Regarding the Total Number of Voting Rights and Total Number of…

Information regarding the total number of voting rights andtotal number of shares of the Company as of May 30, 2025 (Article 223-16 of the General Regulations of theAutorité des Marchés Financiers )Market : NYSE Euronext ParisISIN Code: FR 0010417345DateTotal number of shares Total number of voting rights 05/30/2025 136,973,697Total gross of voting rights: 136,973,697Total net*...
Nasdaq GlobeNewswire
04/06/2025

AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These…

VANCOUVER, BC, June 4, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinseyreport. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot…
PR Newswire
04/06/2025

Launch of a capital increase with preferential subscription rights for nearly 5…

Press releaseLaunch of a capital increase with preferential subscription rights for nearly 5 million eurosIssuance of new shares for an initial total amount of around €5.0 million, with shareholders maintaining their preferential subscription rights (DPS), which may be increased to around €5.7 million if the extension clause is exercised (the “Offer”).Intentions and commitment to subscribe by existing shareholders and Vatel Capital, as a new institutional investor, for a total...
Nasdaq GlobeNewswire
04/06/2025

/C O R R E C T I O N -- Research Grid Ltd/

In a major cardiac imaging trial involving over 600 patients, the AI was able to digitize thousands of pages of patient records in seconds or minutes. This eliminated a 5% human error rate, saved over 24,000 staff hours, and cut data entry costs from $1.5 million to $6,000. In a major cardiac imaging trial involving over 600 patients, the AI was able to digitize thousands of pages of patient records in seconds or minutes. This eliminated a 5% human error rate, saved over 24,000 staff hours…
PR Newswire
04/06/2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – June 4, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 3, 2025, from Atlas Special…
Actusnews Wire
04/06/2025

BASTIDE : Respiratory care therapy: Baywater wins London region tender and…

Caissargues, June 4, 2025 After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region of the United Kingdom, Baywater, a subsidiary wholly owned by Bastide Groupe, has consolidated its leading position in the UK by winning the tender to provide…
Actusnews Wire
04/06/2025

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market…
Actusnews Wire
04/06/2025

Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API…

Press Release Paris – June 4, 2025– EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company's Executive Committee. This appointment is part of EUROAPI's ongoing FOCUS-27 transformation plan and...
Nasdaq GlobeNewswire
04/06/2025

Tursian Skincare Ushers in a New Era in Skin Science with the Power of Three…

At the heart of Tursian's most potent serums and treatments is a synergistic trio of proven actives: At the heart of Tursian's most potent serums and treatments is a synergistic trio of proven actives: Tursian doesn't chase trends — it builds on science. All products have undergonethird-party clinical testingto ensure both performance and tolerability. And beyond surface-level results, every formula is thoughtfully engineered tosupport the skin's microbiome, promotingmicrobial...
PR Newswire
04/06/2025

Alvotech intends to carry out a private placement of approximately 7.5 million…

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE...
Nasdaq GlobeNewswire
04/06/2025

Elsevier Unveils Rigorous Evaluation Framework to Mitigate Risk in Generative AI…

Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst clinicians Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst clinicians NEW YORK , June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has...
PR Newswire
04/06/2025

Coagulation Analyzer Market worth US$5,335.9 million by 2030 with 7.2% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392 Browse in-depth TOC on "Coagulation Analyzer Market" 419 - Tables 45 - Figures 328 - Pages By Based on product,The coagulation analyzers market is divided based on product type into clinical laboratory analyzers and point-of-care testing analyzers. In 2024, the clinical laboratory analyzers...
PR Newswire
04/06/2025

Bioretec Ltd publishes an exemption document relating to its rights issue

TAMPERE, Finland, June 4, 2025 /PRNewswire/ -- Bioretec Ltd ("Bioretec" or the "Company") announced on 28 May 2025 that it is commencing a rights issue, in which Bioretec offers up to 6,156,618 new shares (the "New Shares") for subscription by Bioretec's existing shareholders in accordance with the pre-emptive right of shareholders with a subscription price of EUR 1.50 per New Share (the "Offering"). TAMPERE, Finland , June 4, 2025 /PRNewswire/ -- Bioretec…
PR Newswire
04/06/2025

Yuwell PRIMEDIC Global Partners Conference Held in Germany - Signs Strategic…

Yuwell Chairman, Mr. Alex WU, highlighted PRIMEDIC's 52-year mission of "Saves life. Everywhere." He emphasized Yuwell's commitment to further invest in PRIMEDIC to advice its position as a global leader in first-aid solutions and protect more lives worldwide. Yuwell Chairman, Mr. Alex WU, highlightedPRIMEDIC 's 52-year mission of "Saves life. Everywhere." He emphasizedYuwell 's commitment to further invest inPRIMEDIC to advice its position as a global leader in first-aid…
PR Newswire
04/06/2025

Faraday Factory Has Started Delivery of Superconductor Tapes for 200,000 Ampere…

According to the International Aluminium Institute, aluminum smelting industry has an estimated annual output of 72+ million tons with the average energy intensity of 135 kWh per kilogram. The Hamburg project aims to demonstrate the massive energy-saving potential of superconductor busbars for aluminum smelting, as well as for other electrolysis processes, data centers, solar fields, and railways. According to the International Aluminium Institute, aluminum smelting industry has an…
PR Newswire
04/06/2025

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184…

"Completing enrollment in our Phase 2a MDS study is a major milestone as we continue to validate our mechanism of action targeting innate immune dysregulation," said Dr. David Bearss, CEO of Halia Therapeutics. "This study provides important proof-of-concept data to support the therapeutic potential of HT-6184 in reducing clonal inflammation and improving hematologic outcomes for patients with symptomatic anemia." "Completing enrollment in our Phase 2a MDS study is a…
PR Newswire
04/06/2025
Altri  Comunicati